Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Global Medical REIT Inc. (GMRE)
|
Add to portfolio |
|
|
|
| Price: |
$17.90
| | Metrics |
| OS: |
65.6
|
M
| |
|
|
| Market cap: |
$1.17
|
B
| |
|
|
|
Net debt:
|
$623
|
M
| |
|
|
|
EV:
|
$1.8
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 137.3 | 115.9 | 93.7 | 70.7 | 53.2 | 30.3 | 8.2 | 2.1 |
| Revenue growth | 18.4% | 23.7% | 32.5% | 33.0% | 75.3% | 269.6% | 298.2% | 245.6% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.8 | 0.6 |
| Gross profit | 137.3 | 115.9 | 93.7 | 70.7 | 53.2 | 30.3 | 7.5 | 1.4 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 90.8% | 69.6% |
| Selling, general and administrative | | | | | | | | |
| General and administrative | 16.5 | 16.5 | 11.9 | 6.5 | 5.5 | 5.5 | 4.2 | 0.4 |
| EBIT | 38.5 | 37.0 | 16.2 | 27.1 | 29.5 | 7.3 | -2.2 | -0.1 |
| EBIT margin | 28.0% | 31.9% | 17.3% | 38.3% | 55.5% | 24.2% | -27.0% | -4.4% |
| Pre-tax income | 13.2 | 17.3 | -2.5 | 9.6 | 14.6 | -0.1 | -6.4 | -1.6 |
| Income taxes | 6.5 | 16.2 | -2.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 49.0% | 93.8% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Earnings from continuing ops | 6.6 | 10.7 | -7.7 | 3.4 | 7.7 | -1.8 | -6.4 | -1.6 |
| Earnings from discontinued ops | 6.8 | 1.1 | | | | | | |
| Net income | 13.3 | 11.8 | -7.7 | 3.4 | 7.7 | -1.8 | -6.4 | -1.6 |
| Net margin | 9.7% | 10.2% | -8.3% | 4.8% | 14.4% | -5.8% | -77.4% | -78.0% |
| |
| Diluted EPS | $0.10 | $0.18 | ($0.17) | $0.10 | $0.35 | ($0.09) | ($0.68) | ($6.44) |
| Shares outstanding (diluted) | 65.5 | 60.6 | 46.3 | 33.9 | 22.0 | 19.6 | 9.3 | 0.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|